ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
16 announcements with these filters
Dr. Lal Path Labs' subsidiary completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for Rs.38.00 Crore. The target is now a subsidiary.
Dr. Lal PathLabs' subsidiary, DLPL Dubai, completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana. Sunshine Healthcare is now a step-down subsidiary.
Dr. Lal PathLabs will hold a board meeting on November 04, 2026, to consider and approve standalone and consolidated financial results for the quarter ending September 30, 2026.
Designated persons and the company's Employee Welfare Trust disclosed multiple equity transactions, including ESOP exercises and market sales, in a recent regulatory filing.
Dr. Lal Path Labs Ltd. will acquire a 70% stake in SN Genelab Private Limited for Rs. 168 Crore to strengthen its genomics diagnostics portfolio.
Dr. Lal PathLabs approved the acquisition of a 70% stake in SN Genelab Private Limited for a total consideration of up to ₹199.5 Crore.
Dr. Lal PathLabs discloses share transactions by designated persons and an employee welfare trust under PIT regulations.
Designated persons at Dr. Lal PathLabs Ltd disclosed three equity trades totaling Rs. 0.50 Crore, as mandated under Insider Trading regulations.
Designated persons of Dr. Lal PathLabs Ltd sold equity shares worth a combined ₹0.49 Crore via market sales.
Designated persons and the employee welfare trust of Dr. Lal PathLabs Ltd disclosed share transactions under PIT Regulations. These trades involve ESOP-related activities and market sales.
Dr. Lal Path Labs Ltd.'s subsidiary completed a 30% stake subscription in Neuome Technologies Private Limited for ₹3.50 Crore, making Neuome an associate company.
Dr. Lal PathLabs' subsidiary, Dr. Lal Ventures, has completed the acquisition of a 30% stake in Neuome Technologies Private Limited.
Designated Person Abhishek Maini acquired 500 equity shares via ESOP and subsequently sold 500 shares. This is a routine regulatory disclosure of personal trading activity.
Dr. Lal PathLabs reported insider trading disclosures for share sales by a designated person and the Employee Welfare Trust. These trades involve 33,350 shares total.
Dr. Lal Path Labs Ltd.'s subsidiary will acquire a 70% stake in Dr Lal PathLabs Indomed LLC to expand its diagnostics services in Uzbekistan.
Dr. Lal PathLabs' subsidiary, Dr Lal PathLabs FZCO, has incorporated a new step-down subsidiary, Dr Lal PathLabs Indomed LLC, in Tashkent, Uzbekistan, acquiring a 70% stake.